• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.5590 -0.0112 (-1.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,290
Open 0.5714
Bid (Size) 0.5530 (1,000)
Ask (Size) 0.6100 (200)
Prev. Close 0.5702
Today's Range 0.5530 - 0.5751
52wk Range 0.4600 - 1.550
Shares Outstanding 24,887,446
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lexaria Updates Business Development
July 06, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
June 25, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire

Performance

YTD
-14.5%
-14.5%
1 Month
-1.5%
-1.5%
3 Month
-40.7%
-40.7%
6 Month
-31.6%
-31.6%
1 Year
-45.7%
-45.7%

More News

Read More
News headline image
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
June 23, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
June 17, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
June 09, 2026
Via ACCESS Newswire
News headline image
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
June 03, 2026
Via ACCESS Newswire
News headline image
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
May 19, 2026
Via ACCESS Newswire
News headline image
Lexaria Bioscience Releases Second Episode of Investor Video Series
May 07, 2026
Via ACCESS Newswire
News headline image
Lexaria Updates Progress on Human Study #7
May 05, 2026
Via ACCESS Newswire
News headline image
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
May 01, 2026
Via ACCESS Newswire
Wednesday's session: top gainers and losers ↗
April 29, 2026
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
April 29, 2026
Via Chartmill
News headline image
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
April 29, 2026
Via ACCESS Newswire
News headline image
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
April 23, 2026
Via ACCESS Newswire
News headline image
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
April 21, 2026
Via ACCESS Newswire
News headline image
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
April 15, 2026
Via ACCESS Newswire
News headline image
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
April 07, 2026
Via ACCESS Newswire
News headline image
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
April 07, 2026
Via TheNewswire.com
News headline image
Lexaria to Begin New Human Clinical Study in GLP-1
April 01, 2026
Via ACCESS Newswire
News headline image
Lexaria's Robust Patent Portfolio Continues to Grow
March 26, 2026
Via ACCESS Newswire
News headline image
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
March 24, 2026
Via ACCESS Newswire
News headline image
Lexaria Announces New R&D Plans for 2026
March 04, 2026
Via ACCESS Newswire
News headline image
Lexaria Announces Positive Final Results From Human Pilot Study #5
February 05, 2026
Via ACCESS Newswire
News headline image
Lexaria Awarded Six Additional Patents
January 22, 2026
Via TheNewswire.com
Topics Intellectual Property
News headline image
Lexaria Awarded Six Additional Patents
January 22, 2026
Via ACCESS Newswire

Frequently Asked Questions

Is Lexaria Bioscience Corp. - Common Stock publicly traded?
Yes, Lexaria Bioscience Corp. - Common Stock is publicly traded.
What exchange does Lexaria Bioscience Corp. - Common Stock trade on?
Lexaria Bioscience Corp. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lexaria Bioscience Corp. - Common Stock?
The ticker symbol for Lexaria Bioscience Corp. - Common Stock is LEXX on the Nasdaq Stock Market
What is the current price of Lexaria Bioscience Corp. - Common Stock?
The current price of Lexaria Bioscience Corp. - Common Stock is 0.5590
When was Lexaria Bioscience Corp. - Common Stock last traded?
The last trade of Lexaria Bioscience Corp. - Common Stock was at 07/24/26 04:00 PM ET
What is the market capitalization of Lexaria Bioscience Corp. - Common Stock?
The market capitalization of Lexaria Bioscience Corp. - Common Stock is 13.91M
How many shares of Lexaria Bioscience Corp. - Common Stock are outstanding?
Lexaria Bioscience Corp. - Common Stock has 14M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap